News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Vanguard Portfolio Management LLC has disclosed an 8.05% beneficial ownership stake in Sarepta Therapeutics Inc. (SRPT) through an amended Schedule 13G filing. As of June 30, 2026, Vanguard beneficially owns 8,499,421 shares, holding sole voting power over 121,951 shares and sole dispositive power over …
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%Sarepta Therapeutics (SRPT) has appointed Michael Severino, M.D., as its new CEO, effective July 28, 2026. Despite a recent modest share price gain, the stock has seen significant declines year-to-date and over the past five years. Analysts suggest SRPT could be 28.3% undervalued with …
Sarepta Therapeutics (SRPT) is expected to report a significant year-over-year decline in Q2 earnings and revenues. While analysts have recently become more bullish on the company based on a higher Most Accurate Estimate, Sarepta's Zacks Rank of #4 makes a definitive prediction of an …
CAMBRIDGE, Mass., July 29, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as amended, as …
Sarepta Therapeutics (NASDAQ: SRPT) had approximately 843 employees worldwide as of March 2026, representing a 24.8% decline from 2023. Despite this reduction, the company is actively hiring, with 85 active job postings in 2026. The majority of its workforce is in the United States, …
Sarepta Therapeutics has appointed Michael Severino, an R&D veteran, as its new CEO, combining his role with a seat on the board. This leadership change comes as Sarepta is focusing on the safety data of its drug ELEVIDYS, particularly regarding acute liver injury. Severino's …
Sarepta Therapeutics, known for its Duchenne muscular dystrophy treatments, has appointed Michael Severino, former CEO of Tessera Therapeutics, as its new chief executive. Severino replaces Doug Ingram, who is retiring after nearly a decade. The company has faced scrutiny over the efficacy and safety …
Sarepta Therapeutics has appointed Michael Severino as its new CEO and a Class I director, effective July 28, 2026. Severino replaces Doug Ingram, who is retiring but will remain an adviser for the rest of 2026. Severino's three-year contract includes a $1.18 million base …
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), a company focused on genetic medicine for rare diseases, has appointed Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino will also join the company's Board of Directors, succeeding Doug Ingram, who is retiring and …
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround. The company on Monday announced that Michael Severino, …
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%Sarepta Therapeutics Inc (SRPT) is a commercial-stage biopharmaceutical company focusing on RNA-targeted therapeutics and gene therapy for rare diseases like Duchenne muscular dystrophy. The company's fundamentals are considered healthy with high growth potential, and it is currently regarded as fairly valued. Analysts have given …
Sarepta Therapeutics (SRPT) stock reflects a balancing act where investors are weighing the growing revenue from its Elevidys gene therapy against persistent operating losses. The company's 2024 revenue reached $1.28 billion, with Elevidys emerging as a significant growth driver, yet net losses mounted to …
This article provides the latest stock information for Sarepta Therapeutics Inc (SRPT), including its current price, market capitalization, and key financial metrics. Recent news highlights a 4% stock drop due to Citi flagging a potentially stronger rival in the Duchenne space, and the company …
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce its second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, August 5, 2026. Following the announcement, the company will host a conference call at 4:30 p.m. E.T. to discuss the results, with a live …
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%Shares of Sarepta Therapeutics (SRPT) fell by 4% after Citi reiterated a 'Sell' rating due to anticipated heightened competition in the Duchenne muscular dystrophy (DMD) exon-skipping market. This comes as Dyne Therapeutics' DMD therapy, z-rostudirsen, received FDA application acceptance with Priority Review, potentially offering …
Sarepta Therapeutics (SRPT) experienced a rise in short interest to 32.62% of its float as of June 30th, according to new data. Institutional investors showed mixed activity, with 137 adding shares and 160 decreasing positions in Q1 2026, while insiders recorded one sale and …
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%The FDA has accepted Dyne Therapeutics' application for its Duchenne muscular dystrophy therapy, zeleciment rostudirsen, setting a target action date of January 21, 2027. Analysts predict a smooth approval and significant market share due to its superior efficacy and more convenient dosing compared to …
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%Dyne Therapeutics stock briefly jumped Monday after the FDA agreed to review the company's muscular dystrophy drug. Continue Reading
Sarepta Therapeutics (SRPT) has experienced a significant decline in share price over the past three years. Despite recent FDA approval for its Duchenne muscular dystrophy therapies, the stock appears overvalued based on its P/E ratio, trading at 27.9x earnings compared to the biotech industry …
Sarepta Therapeutics (SRPT) shares jumped 35% after releasing early clinical data for its rare muscle disorder programs, DM1 and FSHD1. While some analysts found the data promising, others expressed caution due to limitations in the data and safety concerns. The company's investigational siRNA treatment …
This article from Stock Traders Daily discusses the volatility of Sarepta Therapeutics Inc. (NASDAQ: SRPT), highlighting conflicting sentiment across different time horizons. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis. The analysis suggests …
Sarepta Therapeutics (SRPT) is being re-evaluated after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, Duchenne muscular dystrophy therapies. While the stock has seen a recent 30-day rebound, its long-term shareholder returns remain negative. The article explores whether the …
Sharemaestro market context Price below Trend Line 52 weeks -24.7% · Next-week setup negative 25.3%Search by ticker symbol or company name and select a result to open its chart.